Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00846989 | Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension | PHASE1 | COMPLETED | 276 | — | — | Jan 1, 2009 | Apr 1, 2009 | Dec 19, 2020 | 29 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RKI983A | DRUG | RKI983 0.05 % twice daily |
| Latanoprost | DRUG | Latanoprost 0.005 % once a day |
Inclusion Criteria: * Females must be post-menopausal or surgically sterile, or must use concomitantly two acceptable forms of effective contraception * Clinical diagnosis of POAG or OH * For study eyes not previously treated with anti-glaucoma medications * IOP must be ≥ 22 mm Hg at least at tw...